Antiproliferative effects of preservative-free triamcinolone acetonide on cultured human retinal pigment epithelial cells

Medical Science Monitor

Volumn 15, Issue 8, 2009, Pages

  Kaczmarek, Radosław ^a   Szurman, Peter ^b   Misiuk Hojło, Marta ^a   Grzybowski, Andrzej ^c  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c City Hospital   (Poland)

Author keywords

Proliferative vitreoretinopathy; Triamcinolone acetonide

Indexed keywords

PRESERVATIVE; TRIAMCINOLONE ACETONIDE;

ARTICLE; CALORIMETRY; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACTIVITY; DRUG EFFECT; DRUG INHIBITION; DRUG MECHANISM; HUMAN; HUMAN CELL; IN VITRO STUDY; INCUBATION TIME; PIGMENT EPITHELIUM;

BIOLOGICAL ASSAY; CELL DEATH; CELL PROLIFERATION; CELL SURVIVAL; CELLS, CULTURED; EPITHELIAL CELLS; HUMANS; PIGMENT EPITHELIUM OF EYE; PRESERVATIVES, PHARMACEUTICAL; TRIAMCINOLONE ACETONIDE;

EID: 68449105010     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Cardillo JA, Stout JT, LaBree L et al: Post-traumatic proliferative vitreoretinopathy. The epidemiologic profile, onset, risk factors, and visual outcome. Ophthalmology, 1997; 104: 1166-1173
2. Rachal WF, Burton TC: Changing concepts of failures after retinal detachment surgery. Arch Ophthalmol, 1979; 97: 480-483 (Pubitemid 9098740)
3. Machemer R, Sugita G, Tano Y: Treatment of intraocular proliferations with intravitreal steroids. Trans Am Ophthalmol Soc, 1979; 77: 171-180 (Pubitemid 10072805)
4. Antcliff RJ, Spalton DJ, Stanford MR et al: Intravitreal triamcinolone for uveitic cystoid macular edema: an optical coherence tomography study. Ophthalmology, 2001; 108: 765-772 (Pubitemid 32238474)
5. Tano Y, Chandler D, Machemer R: Treatment of intraocular proliferation with intravitreal injection of triamcinolone acetonide. Am J Ophthalmol, 1980; 90: 810-816 (Pubitemid 11199134)
6. Martidis A, Duker JS, Greenberg PB, Rogers AH: Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology, 2002: 109: 920-927 (Pubitemid 34465226)
7. Jonas JB, Kreissig I, Sofker A, Degenring RF: Intravitreal injection of triamcinolone for diffuse diabetic macular edema. Arch Ophthalmol, 2003; 121: 57-61 (Pubitemid 36401766)
8. Danis RP, Ciulla TA, Pratt LM, Anliker W: Intravitreal triamcinolone acetonide in exudative age-related macular degeneration. Retina, 2000; 20: 244-250 (Pubitemid 30436775)
9. Jonas JB, Degenring RF, Kreissig I et al: Exudative age-related macular degeneration treated by intravitreal triamcinolone acetonide. A prospective comparative nonrandomized study. Eye, 2005: 19: 163-170
10. Jaissle GB, Szurman P, Bartz-Schmidt KU: Ocular side effects and complications of intravitreal triamcinolone acetonide injection. Ophthalmologe, 2004; 101: 121-128 (Pubitemid 38295554)
11. Kivilcim M, Peyman GA, El-Dessouky ES et al: Retinal toxicity of triamcinolone acetonide in silicone-filled eyes. Ophthalmic Surg Lasers, 2000; 31: 474-478 (Pubitemid 30841239)
12. McCuen BW II, Bessler M, Tano Y et al: The lack of toxicity of intravitreally administered triamcinolone acetonide. Am J Ophthalmol, 1981; 91: 785-788 (Pubitemid 11078533)
13. Schlaegel TF, Wilson FM: Accidental intraocular injection of depot corticosteroids. Trans Am Acad Ophthalmol Otol, 1974; 78: 847-855
14. Hida T, Chandler D, Arena JE, Machemer R: Experimental and clinical observations of the intraocular toxicity of commercial corticosteroid preparations. Am J Ophthalmol, 1986; 101: 190-195 (Pubitemid 16136575)
15. Felix H: Permeabilized cells. Anal Biochem, 1982; 120: 211-234
16. Chandler DB, Rozakis G, de Juan E Jr, Machemer R: The effect of triamcinolone acetonide on a refined experimental model of proliferative vitreoretinopathy. Am J Ophthalmol, 1985; 99: 686-690 (Pubitemid 15059943)
17. Hernaez-Ortega MC, Soto-Pedre E: A simple and rapid method for purifi cation of triamcinolone acetonide suspension for intravitreal injection. Ophthalmic. Surg Lasers Imaging, 2004; 35: 350-351
18. Jaissle GB, Szurman P, Bartz-Schmidt KU: Recommendation for the procedure of intravitreal injections of the German Retina Society, the German Society of Ophthalmology (DOG) and the German Professional Association of Ophthalmology (BVA). Klin Monatsbl Augenheilkd, 2005; 222: 390-395
19. Jonas JB, Hayler JK, Sofker A, Panda-Jonas S: Intravitreal injection of crystalline cortisone as adjunctive treatment of proliferative diabetic retinopathy. Am J Ophthalmol, 2001; 131: 468-471 (Pubitemid 32273433)
20. Nishimura A, Kobayashi A, Segawa Y et al: Isolating triamcinolone acetonide particles for intravitreal use with a porous membrane filter. Retina, 2003; 23: 777-779 (Pubitemid 38040576)
21. Dunn KC, Aotaki-Keen AE, Putkey FR, Hjelmeland LM: ARPE-19, a human retinal pigment epithelial cell line with differentiated properties. Exp Eye Res, 1996; 62: 155-169 (Pubitemid 26140102)
22. Martin S, Reutelingsperger CP, McGahon AJ et al: Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: inhibition by overexpression of Bcl-2 and Abl. J Exp Med, 1995; 182: 1545-1556
23. Vermes I, Haanen C, Steffens-Nakken H, Reutelingsperger CP: A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J Immunol Meth, 1995; 184: 39-51
24. Yeung CK, Chan KP, Chan CK et al: Cytotoxicity of triamcinolone on cultured human retinal pigment epithelial cells: comparison with dexamethasone and hydrocortisone. Jpn J Ophthalmol, 2004; 48: 236-242 (Pubitemid 38691431)
25. Yeung CK, Chan KP, Chiang SWY et al: The toxic and stress responses of cultured human retinal pigment epithelium (ARPE19) and human glial cells (SVG) in the presence of triamcinolone. Invest Ophthalmol Vis Sci, 2003; 44: 5293-5300
26. Jonas JB, Hayler JK, Panda-Jonas S: Intravitreal injection of crystalline cortisone as adjunctive treatment of proliferative vitreoretinopathy. Br J Ophthalmol, 2000; 84: 1064-1067
27. Modarres M, Parvaresh MM, Peyman GA: Accidental subretinal injection of triamcinolone acetonide. Ophthalmic Surg Lasers, 1998; 29: 935-938 (Pubitemid 28524434)
28. Moshfeghi DM, Kaiser PK, Bakri SJ et al: Presumed sterile endophthalmitis following intravitreal triamcinolone acetonide injection. Ophthalmic Surg Lasers Imaging, 2005; 36: 24-29 (Pubitemid 40128598)
29. Ruhmann AG, Berliner DL: Effect of steroids on growth of mouse fibroblasts in vitro. Endocrinology, 1965; 76: 916-927
30. Sasaki H, Tei C, Nishida K, Nakamura J: Effect of ophthalmic preservatives on serum concentration and local irritation of ocularly applied insulin. Bio Pharm Bull, 1995; 18: 169-171
31. Sunalp M, Wiedemann P, Sorgente N, Ryan SJ: Effects of cytotoxic drugs on proliferative vitreoretinopathy in the rabbit cell injection model. Curr Eye Res, 1984; 3: 619-623 (Pubitemid 14173065)
32. Sutter FKP, Gillies MC: Pseudo-endophthalmitis after intravitreal injection of triamcinolone. Br J Ophthalmol, 2003; 87: 972-974
33. Ungphaiboon S, Nittayananta W, Vuddhakul V et al: Formulation and efficacy of triamcinolone acetonide mouthwash for treating oral lichen planus. Am J Health Syst Pharm, 2005; 62: 485-491 (Pubitemid 40332258)
34. Wiedmann TS, Bhatia R, Wattenberg LW: Drug solubilization in lung surfactant. J Control Release, 2000; 65: 43-47
35. Szurman P, Kaczmarek R, Spitzer MS et al: Differential toxic effect of dissolved triamcinolone and its crystalline deposits on cultured human retinal pigment epithelium (ARPE19) cells. Exp Eye Res, 2006; 83: 584-592 (Pubitemid 43902780)
36. Shaikh S, Ho S, Engelmann LA, Klemann SW: Cell viability effects of triamcinolone acetonide and preservative vehicle formulations. Br J Ophthalmol, 2006; 90: 233-236 (Pubitemid 43163858)